Navigation Links
Leading Pharmaceutical Communication Executives Gather for the 1st Annual Pharmaceutical Public Relations Symposium
Date:10/8/2007

NEW YORK, Oct. 8 /PRNewswire/ -- ExL Pharma, Cision and the PRSA have joined together to bring the pharmaceutical, medical device and biotech public relations executives the first Pharmaceutical Public Relations Symposium in conjunction with the PRSA 2007 International Conference. This one-day event will cover the key issues and challenges that these companies face in an industry that is under ongoing political and media scrutiny, most notably as we head into the 2008 election year.

The symposium offers perspectives from top pharmaceutical industry professionals representing companies such as: Pfizer, Wyeth, EMD-Serono, CCW Worldwide, Feinstein Kean Healthcare, Cision, ExL Pharma, and more. In addition, representatives from the FDA will speak on "Communicating More Effectively with the FDA" which will highlight key items on the FDA agenda in 2008. Topics of discussion will include enhancing corporate reputation, social responsibility, issues management, measurement of PR activities and merger or acquisition public relations strategies.

Bryon Main, Managing Director with ExL Pharma, had this to share about the upcoming event, "It is exciting to have partnered with PRSA and Cision to bring the pharmaceutical public relations professionals a one-day refresher symposium on top-of-mind issues for the industry as we head into 2008. This industry will be under even higher scrutiny in an election year and this event examines many key issues. We have a distinguished faculty ready to share ideas, as well as best practices, with attendees on how they can help improve the perception amongst key stakeholders."

The symposium is scheduled for October 23, 2007 at the Philadelphia Marriott hotel in downtown Philadelphia and is sponsored by PRSA Health Academy and CCW Worldwide. To view the full program agenda and/or to register, please visit http://www.exlpharma.com

*Please mention keycode EXLPHARMA

About ExL Pharma

ExL Pharma, a division of ExL Events, Inc., is an emerging leader in developing innovative, educational events that serve the healthcare community and allied professionals. Behind our diverse conference portfolio, our experienced team conducts extensive market research and targeted outreach. The results translate into innovative, high-quality conference events designed to exceed the dynamic informational needs of the healthcare community. ExL Pharma is well known as the provider of the PR & Communications Summit for Pharmaceutical, Biotech and Medical Technology, which is scheduled for its 4th run on July 14-15, 2008.

About the Public Relations Society of America (PRSA)

The Public Relations Society of America (http://www.prsa.org), headquartered in New York City, is the world's largest organization for public relations professionals with nearly 32,000 professional and student members. PRSA is organized into 109 Chapters nationwide and 20 Professional Interest Sections and Affinity Groups, which represent business and industry, counseling firms, independent practitioners, military, government, associations, hospitals, schools, professional services firms and nonprofit organizations. The Public Relations Student Society of America (PRSSA) has 285 Chapters at colleges and universities throughout the United States.

About Cision:

Cision, formerly known as Bacon's, Delahaye and multivision, delivers the insight and media intelligence that improves communication performance and builds reputations. As a leading global provider of media research, distribution, monitoring and evaluation services, we ensure consistent global service; with the resources needed to grow with our clients and the public relations profession.


'/>"/>
SOURCE ExL Pharma
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Visions, Part II: Preizler sees IT leading incremental health system change
2. Waisman director leading early stages of the Wisconsin Institutes for Discovery
3. NimbleGen partners with leading researchers
4. Leading global Big Pharma companies of 2005
5. Leading cancer institute to install three TomoTherapy systems
6. The worlds leading biotech companies
7. Analyzing Trace-Level Impurities of a Pharmaceutical Intermediate Using an LCQ Deca Ion Trap Mass Spectrometer and the Mass Frontier Software Package
8. Practical Applications of HyperDSC in a Pharmaceutical Laboratory
9. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
10. Deltanoid Pharmaceuticals begins phase II osteoporosis study
11. Doing the pharmaceutical tango
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... BELLINGHAM, Washington, USA, and CARDIFF, UK (PRWEB) , ... ... ... neural circuits with very high precision light to control cells — optogenetics — ... brain. In the current state of the art, spatially patterned light projected via ...
(Date:12/8/2016)... Oxford Gene Technology ... Palette an anpassbaren SureSeq™ NGS-Panels mit dem Start ... ein schnelles und kostengünstiges Studium der Varianten bei ... Erkennung von Einzel-Nukleotid-Variationen (Single Nucleotide Variation, SNV) und ... Panel und ermöglicht eine individuelle Anpassung durch die ...
(Date:12/8/2016)... , Dec. 8, 2016  Anaconda BioMed S.L., a ... of the next generation neuro-thrombectomy system for the treatment ... Tudor G. Jovin, MD to join its Scientific Advisory ... a strategic network of scientific and clinical experts to ... of the ANCD BRAIN ® to its clinical ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... exceptionally efficient human mesenchymal stem/stromal cell (hMSC) expansion medium. This single ... engineered to radically streamline culture processes, minimize processing time, significantly decrease production ...
Breaking Biology Technology:
(Date:11/17/2016)... , Nov. 17, 2016 Global Market Watch: ... Biobanks (Disease-Based Banks, Population-Based Banks and Academics) market is to ... for Private Biobanks shows the highest Compounded Annual Growth Rate ... region during the analysis period 2014-2020. North ... of 9.95% followed by Europe at ...
(Date:11/15/2016)...  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... gut microbiome, today announced the pricing of an ... common stock and warrants to purchase 50,000,000 shares ... the public of $1.00 per share and accompanying ... offering, excluding the proceeds, if any from the ...
(Date:11/14/2016)... SANTA CLARA, Calif. , Nov. 14, ... of the biometric identification market, Frost & ... Global Frost & Sullivan Award for Visionary ... leading player in the biometric identification market ... a multi-modal verification solution for instant, seamless, ...
Breaking Biology News(10 mins):